Healthcare / Health Information ServicesTaipei Exchange
$56.30
-0.10 (-0.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-30.2M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.3B
P/E
63.3x
↑EV/EBITDA
32.2x
↑ROE
5.0%
↑Gross Margin
59.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+91.5%
FCF CAGR
—
FCF margin
-8.0%
FCF / Net income
-0.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $378.8M · net income $83.4M · FCF $-30.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $378.8M | $378.8M | $337.5M | $94.0M | $53.9M |
| Net Income | $83.4M | $83.4M | $30.3M | $-42.0M | $136.5M |
| EBITDA | $148.5M | $148.5M | $78.0M | $-16.9M | $154.7M |
| EPS | — | — | 0.31 | -0.44 | 1.54 |
| Gross Margin | 59.4% | 59.4% | 61.6% | 49.6% | 72.2% |
| Operating Margin | 10.2% | 10.2% | 9.0% | -113.6% | -133.6% |
| Net Margin | 22.0% | 22.0% | 9.0% | -44.7% | 253.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 12.26 | 12.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-30.2M | $-30.2M | $13.0M | $-46.6M | $-68.2M |
| Returns | |||||
| ROE | 5.0% | 5.0% | 1.6% | -2.2% | 8.3% |
| Valuation | |||||
| P/E | 63.26 | 63.26 | 232.58 | — | 44.68 |
| EV/EBITDA | 32.22 | 32.22 | 88.34 | — | 39.38 |
| P/B | 3.17 | 3.17 | 3.72 | 4.63 | 3.71 |
| Growth & Yield | |||||
| Revenue Growth | 12.2% | 12.2% | 259.1% | 74.4% | — |
| EPS Growth | — | — | 170.5% | -128.6% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.31 → n/d
Residual
-25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.